EYE-GO A/S - CVR: 36957670

2022, DKK

15.06.2023

Bruttoresultat

-729'

Primær drift

-2.006'

Årets resultat

-645'

Aktiver

20.654'

Kortfristede aktiver

11.075'

Egenkapital

4.706'

Afkastningsgrad

-10 %

Soliditetsgrad

23 %

Likviditetsgrad

106 %

Resultat

15.06.2023

Årsrapport	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Nettoomsætning
Bruttoresultat	-729.160	-4.487.992	-3.187.784	-3.028.217	-7.855.430	-5.301.699	-2.358.631
Resultat af primær drift	-2.005.735	-6.952.571	-4.420.975	-5.098.614	-10.803.285	-10.790.711	-2.738.631
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0
Finansielle indtægter	31.932	31.282	18.768	69.423	0	0	0
Finansieringsomkostninger	-310.884	-279.878	-67.224	0	0	0	0
Andre finansielle omkostninger	0	0	0	-38.846	-12.562	-111.159	-37
Resultat før skat	-2.284.687	-7.201.167	-4.469.431	-5.068.037	-10.815.847	-10.901.870	-2.738.668
Resultat	-644.647	-5.654.295	-3.492.115	-3.956.201	-7.043.685	-10.901.870	-2.738.668
Forslag til udbytte	0	0	0	0	0	0	0

Aktiver

15.06.2023

Årsrapport	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	2.027.071	2.625.858	2.528.308	4.321.071	5.323.860	1.052.849	115.068
Likvider	9.048.168	228.233	6.429.715	760.395	1.201.436	11.958.506	129.377
Kortfristede aktiver	11.075.239	2.854.091	8.958.023	0	0	0	0
Immaterielle aktiver og goodwill	7.454.728	0	0	0	0	0	4.520.000
Finansielle anlægsaktiver	50.547	50.547	50.547	50.547	50.547	50.547	0
Materielle aktiver	2.073.454	7.615	7.615	7.615	22.213	15.136	0
Langfristede aktiver	9.578.729	58.162	58.162	58.162	72.760	65.683	4.520.000
Aktiver	20.653.968	2.912.253	9.016.185	5.139.628	6.598.056	13.077.038	4.764.445

Aktiver

15.06.2023

Passiver

15.06.2023

Årsrapport	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Forslag til udbytte	0	0	0	0	0	0	0
Egenkapital	4.706.358	-2.849.044	2.805.251	4.630.699	5.586.902	12.630.587	4.721.352
Hensatte forpligtelser	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0
Anden langfristet gæld	5.546.391	5.264.818	5.104.900	28.815	0	0	0
Leverandører af varer og tjenesteydelser	262.686	109.999	764.174	304.000	531.197	90.384	38.093
Kortfristede forpligtelser	10.401.219	496.479	1.106.034	480.114	1.011.154	446.451	0
Gældsforpligtelser	15.947.610	5.761.297	6.210.934	0	0	0	0
Forpligtelser	15.947.610	5.761.297	6.210.934	0	0	0	0
Passiver	20.653.968	2.912.253	9.016.185	5.139.628	6.598.056	13.077.038	4.764.445

Passiver

15.06.2023

Nøgletal

15.06.2023

Årsrapport	2022 15.06.2023	2021 23.05.2022	2020 02.07.2021	2019 22.05.2020	2018 31.05.2019	2017 19.06.2018	2015 30.06.2017
Afkastningsgrad	-9,7 %	-238,7 %	-49,0 %	-99,2 %	-163,7 %	-82,5 %	-57,5 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-13,7 %	198,5 %	-124,5 %	-85,4 %	-126,1 %	-86,3 %	-58,0 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-645,2 %	-2.484,1 %	-6.576,5 %	Na.	Na.	Na.	Na.
Soliditestgrad	22,8 %	-97,8 %	31,1 %	90,1 %	84,7 %	96,6 %	99,1 %
Likviditetsgrad	106,5 %	574,9 %	809,9 %	Na.	Na.	Na.	Na.

Resultat

15.06.2023

Gæld

15.06.2023

Årsrapport

15.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 15.06.2023)

Information om virksomhedens regnskabsklasse:The annual report of EYE-GO A/S for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

15.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-14

Oplysning om usædvanlige forhold:Management is responsible for ensuring that the Company’s capital resources are sound at any time and that sufficient liquidity is available to meet the Company's current and future liabilities as they fall due. The company has raised additional capital in January 2023 to support the company’s growth strategy and expect to continuously raise the necessary capital to support the company's growth strategy. Based on the above, Management is of the opinion that the Company has sufficient capital resources for the coming year, and accordingly, presents the annual report on a going concern basis.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of EYE-GO A/S for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:EYE-GO develops disruptive eye care technology that improves the quality of life of people around the world suffering from severe and chronic eye conditions. Our MistGo® product is a novel ocular drug delivery system that is the first viable and truly revolutionary replacement of the eye drop bottle. MistGo® works by micro-dosing a thin mist into the eye and is part of the next generation delivery systems capable of administering micro-doses for preservative-free liquids. MistGo® is the only system effectively removing all the well-known barriers from eye-drop bottles. Patients receive the optimal dose with precise installation every time minimizing systemic exposure. The product has an eye interface avoiding contamination and ensuring that no parts of the product touch the ocular surface. The technology behind transforming the 6 µL into a precisely targeted mist is patented in the USA, Europe, and Japan. In 2022 we have finetuned the MistGo® product and started test of customers formulations. We are now in the process of developing the first production line. Our business model is to license to pharma companies against milestone payments and generate recurring revenue from long-term supply agreements. EYE-GO targets pharma companies with prescription (Rx) medicine for treatment of chronic eye diseases. The primary segments are glaucoma (a $3. 2B US market) and dry eye disease (“DED”, a $1. 5B US market). Secondary segments are presbyopia (with expected double digit $B revenue within 5-10 years) and myopia. MistGo® is for young companies (new innovative delivery system for new innovative drugs) as well as established companies (life-cycle extension of current drugs).